SMA

Branaplam (LMI 070) is a highly potent, selective and orally active small molecule SMN2 splicing modulator.

SMA-12b is an analog of the immunomodulatory parasite product ES-62 that has immunomodulatory activity, can modify the expression of many inflammatory response genes, increase the expression of many genes related to antioxidant responses, and can be used in the study of rheumatoid arthritis (RA) and other autoimmune diseases.

SMARCA-BD ligand 1 for Protac is a compound that binds to SMARCA2, the BAF ATPase subunit, utilizing Protac technology to degrade SMARCA2.

Bismaleimide (XU 292A) has heat resistance, oxidation resistance and radiation resistance, and can be used to prepare electrical insulation materials, wear-resistant materials, reinforced plastic additives, grinding wheel adhesives, etc.

Rosmarinic acid (Labiatenic acid) is widely found in plants and has antioxidant, anti-inflammatory, and antibacterial activities. It inhibits MAO-A, MAO-B, and COMT with IC50 of 50.1, 184.6, and 26.7 μM respectively.

Losmapimod (GSK-AHAB) (GW856553X; SB856553; GSK-AHAB) is a specific, potent, and orally active p38 MAPK inhibitor (pKi: 8.1 7.6 for p38α β).

Rosmanol has antioxidant activity, it can activate the antioxidant response element. Rosmanol has biphasic modulation of GABAA receptors, demonstrates CNS activity in mouse models of antinociception, antidepressant and anxiolysis. Rosmanol potently induce

SMARCA-BD ligand 1 for Protac dihydrochloride binds to the BAF ATPase subunit SMARCA2 and is used for degrading SMARCA2 based on PROTAC.

SMANT hydrochloride (N-(4-bromophenyl)-3-(3,5-dimethylpiperidin-1-yl)propanamide hydrochloride) is an antagonist of Smoothened accumulation.

SGC-SMARCA-BRDVIII is a potent and selective inhibitor of SMARCA2, SMARCA4, PB1(2), PB1(3), and PB1(5) with Kds of 35 nM, 36 nM, 3.7 μM, 2.0 μM, and 13 nM, respectively.

Fosmanogepix (APX001) is a first-in-class, orally available broad-spectrum antifungal agent. It acts as an N-phosphonooxymethyl prodrug that undergoes rapid and complete metabolism by systemic alkaline phosphatases. This metabolism leads to the formation of the active moiety, APX001A. Fosmanogepix (APX001), with its ability to target the highly conserved Gwt1 fungal enzyme, holds great potential for the development of treatments against invasive fungal infections.

Furanoeudesma 1,3-diene is a useful organic compound for research related to life sciences and the catalog number is T124026.

Clausmarin A is a useful organic compound for research related to life sciences and the catalog number is T124419.

Chasmanthin is a useful organic compound for research related to life sciences and the catalog number is T125399.

14-Hydroxy-7-O-methylrosmanol is a useful organic compound for research related to life sciences. The catalog number is T125437 and the CAS number is 197649-67-5.

Osmanthuside H is a useful organic compound for research related to life sciences. The catalog number is T125796 and the CAS number is 149155-70-4.

12-O-Acetylrosmarinine is a useful organic compound for research related to life sciences and the catalog number is T125966.

Rosmaquinone is a useful organic compound for research related to life sciences and the catalog number is T126198.

SMAP-2 is an orally bioavailable activator of phosphatase 2A (PP2A) which binds to the PP2A Aα scaffold subunit to drive conformational changes in PP2A. It inhibits the growth of KRAS-mutant lung cancers .

Compound I-291, also known as PROTAC SMARCA2 4-degrader-30, targets the catalytic subunits of the SWI SNF complex, specifically SMARCA2 and SMARCA4. It effectively degrades SMARCA2 in A549 and MV411 cells, as well as SMARCA4 in MV411 cells, with a degradation concentration (DC50) of less than 100 nM.

SMARCA2 4-ligand-3, a PROTAC target protein ligand (Ligands for Target Protein for PROTACs), is utilized in synthesis.

PROTAC SMARCA2 4-degrader-29 (Compound I-279) serves as a degrader for the catalytic subunits SMARCA2 and SMARCA4 of the SWI SNF complex. In A549 cells, this compound effectively degrades SMARCA2 with a DC50 value of less than 100 nM, and similarly degrades SMARCA4 in MV411 cells with a DC50 under 100 nM.

PROTAC SMARCA2 4-degrader-25 is a PROTAC that targets SMARCA2 4. It consists of the E3 ligase ligand (2S,4R)-4-Hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, a PROTAC Linker (S)-2-Amino-3,3-dimethylbutanoic acid, and the target protein ligand SMARCA2 4-ligand-3. The conjugate of the E3 ubiquitin ligase ligand and Linker is (S,R,S)-AHPC.

Lu-AAZTA-NI-PSMA-093, a bivalent radiopharmaceutical agent designed for prostate cancer treatment, improves tumor targeting and retention. This is achieved by integrating a hypoxia-sensitive nitroimidazole (NI) group with a prostate-specific membrane antigen (PSMA) targeting moiety.